Patients with HER-2 high-expression (IHC 3 + /2 +) mUC who received the combination treatment in the uroepithelial carcinoma (UC) portion of the same trial achieved ORR of 36.7%, mPFS of 6.9 m and mOS of 11.0 m. This evidence concerns the gene ERBB2 and urothelial carcinoma.